Department of Vascular Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland -
Vascular Unit, Department of Surgery, University Hospital of Ioannina and School of Medicine, Ioannina, Greece -
J Cardiovasc Surg (Torino). 2024 Apr;65(2):124-131. doi: 10.23736/S0021-9509.24.12995-3. Epub 2024 Apr 18.
We performed a systematic review and meta-analysis to assess the existing published evidence regarding the safety and efficacy of the endovascular aortic repair with chimney technique (ch-EVAR) and physician-modified stent-grafts (PMSGs) for the treatment of pararenal aortic aneurysm repair.
A systematic search of all relevant studies reported until October 2023 according to the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines was performed. The pooled 30-day mortality, peri- and postoperative complication rates were estimated using fixed or random effect methods.
A total of 679 study titles were identified by the initial search strategy, of which 16 were considered eligible for inclusion in the meta-analysis. A total of 1094 patients (ch-EVAR N.=861 and PMSG N.=233) (90% male) were identified. The pooled 30-day mortality rate was 3.4% for ch-EVAR and 2.6% for PMSG. The major adverse events (MAE) in the early period was 14.7% for ch-EVAR and 18.5% PMSG, respectively. Higher occlusion rate was observed of the chimney stents grafts (8.2%) than the bridging stents (1.4%) during the follow-up period.
Ch-EVAR and physician-modified technology are safe with low 30-day mortality in elective settings for pararenal aortic aneurysms repair. No significant differences were seen between the two surgical methods regarding the early major adverse events rate. However, higher occlusion rate for the chimneys can be expected over time.
我们进行了系统评价和荟萃分析,以评估腔内主动脉修复加烟囱技术(ch-EVAR)和医生改良支架移植物(PMSG)治疗肾旁主动脉瘤修复的安全性和有效性的现有证据。
根据 PRISMA(系统评价和荟萃分析的首选报告项目)指南,对截至 2023 年 10 月报告的所有相关研究进行了系统搜索。使用固定或随机效应方法估计 30 天死亡率、围手术期并发症发生率的汇总值。
通过初始搜索策略共确定了 679 个研究标题,其中 16 个被认为符合纳入荟萃分析的条件。共纳入 1094 例患者(ch-EVAR N=861 和 PMSG N=233)(90%为男性)。ch-EVAR 的 30 天死亡率为 3.4%,PMSG 为 2.6%。ch-EVAR 的早期主要不良事件(MAE)发生率为 14.7%,PMSG 为 18.5%。在随访期间,烟囱支架移植物的闭塞率(8.2%)高于桥接支架(1.4%)。
在选择性肾旁主动脉瘤修复中,ch-EVAR 和医生改良技术是安全的,30 天死亡率低。两种手术方法在早期主要不良事件发生率方面没有显著差异。然而,随着时间的推移,烟囱的闭塞率可能会增加。